Completed PHASE3 INTERVENTIONAL 2-arm NCT00211965

StaphVAX Immunogenicity and Safety in Orthopaedic Joint Surgery

A Multicenter, Randomized, Placebo-Controlled, Double-Blinded Study to Evaluate Safety and Immunogenicity of StaphVAX®, a Bivalent Staphylococcus Aureus Glycoconjugate Vaccine in Adult Patients Receiving an Orthopedic Prosthetic Implant

Sponsor: Nabi Biopharmaceuticals

Conditions Staphylococcal Infections

Interventions S. aureus Types 5 and 8 Capsular Polysaccharide Conjugate placebo

Updated 7 times since 2017 Last updated: Dec 26, 2007 Started: Apr 30, 2005 Primary completion: May 31, 2006 Completion: Aug 31, 2006

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE3 trial investigates Staphylococcal Infections and is currently completed. Nabi Biopharmaceuticals leads this study, which shows 7 recorded versions since 2005 — indicating limited longitudinal coverage. Longitudinal tracking of infectious disease trials helps identify durability of treatment effects.

Status Flow

Change History

7 versions recorded

Jan 2026 — Present [monthly]

Completed PHASE3
Sep 2024 — Present [monthly]

Completed PHASE3
Jul 2024 — Sep 2024 [monthly]

Completed PHASE3
Jan 2021 — Jul 2024 [monthly]

Completed PHASE3
Jun 2018 — Jan 2021 [monthly]

Completed PHASE3

▶ Show 2 earlier versions

Feb 2017 — Jun 2018 [monthly]

Completed PHASE3
Jan 2017 — Feb 2017 [monthly]

Completed PHASE3

First recorded

Apr 2005

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Nabi Biopharmaceuticals
Public Health England

Data source: Nabi Biopharmaceuticals

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Stanmore, United Kingdom